Moreover, such differences could explain why MLR retained its significance when the multivariate analysis was restricted to triple negative and HER2-positive breast cancer patients (HR 1.92, 95% CI: 1.15–3.22, p = 0.013). Here, ERBB2 is linked to breast carcinoma.